Add-on Acquisition • Life Science

InvoX Pharma Acquires F-star Therapeutics

On June 23, 2022, InvoX Pharma acquired life science company F-star Therapeutics for 161M USD

Acquisition Context

This is InvoX Pharma’s 1st transaction in the Life Science sector.
This is InvoX Pharma’s largest (disclosed) transaction.
This is InvoX Pharma’s 1st transaction in the United Kingdom.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	June 23, 2022
Target	F-star Therapeutics
Sector	Life Science
Buyer(s)	InvoX Pharma
Deal Type	Add-on Acquisition
Deal Value	161M USD
Advisor(s)	Morgan Stanley (Financial) Mintz Levin Cohn Ferris Glovsky and Popeo (Legal)

Target Company

F-star Therapeutics

Cambridge, United Kingdom

F-star Therapeutics is a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases, through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star Therapeutics is based in Cambridge, United Kingdom.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

InvoX Pharma

London, United Kingdom

Category	Company
Sector	Life Science

DESCRIPTION

InvoX Pharma focuses on R&D and business development activities outside of China, with a core focus on oncology and respiratory therapeutics. InvoX Pharma is based in London, United Kingdom.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: United Kingdom	1 of 1
Year: 2022	1 of 1
Size (of disclosed)	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - United Kingdom M&A - 2022 M&A